Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinibversusbest available therapy

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians

(2011) E. N. Oliva et al.   HAEMATOLOGICA

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

(2009) F. Passamonti et al.   BLOOD

What changes in health-related quality of life matter to multiple myeloma patients? A prospective study

(2009) Ann K. Kvam et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

(2008) F. Cervantes et al.   BLOOD

Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders

(2008) F Cervantes et al.   LEUKEMIA